查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193095

分子细胞遗传学市场：按产品、技术、应用、最终用户分类：2021-2031 年全球机遇分析和行业预测

Molecular Cytogenetics Market By Product, By Technique, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 310 Pages | 商品交期: 2-3个工作天内

价格

全球分子细胞遗传学市场预计到 2021 年将达到 22.335 亿美元，到 2031 年将达到 51.4655 亿美元，复合年增长率为 8.7%。

分子细胞遗传学包括染色体生物学以及分子细胞遗传学技术在生物学和医学中的应用。 它包括染色体和细胞核的结构和功能建立、基因组突变、表达和进化、染色体畸变以及致癌和医学遗传学中的基因组变异。 测试涉及识别特定基因和位点（分子），同时用萤光显微镜直接观察细胞和染色体，并且远未过时并积极参与尖端诊断和研究。

根据美国国家生物技术信息中心 (NCBI) 的数据，2020 年将新增 1930 万癌症患者（1810 万不包括非黑色素瘤皮肤癌），约 1000 万（990 万（不包括非黑色素瘤皮肤癌）癌症）估计死于癌症。 随着细胞内 DNA 改变（突变）引起的癌症疾病在所有年龄组中蔓延，对分子细胞遗传学诊断技术的需求正在增加。

此外，生物技术公司引入尖端诊断技术、对严重癌症疾病的准确诊断的需求不断增加，以及新兴经济体中需要和训练有素的介入病理学家的存在，预计将推动分子疗法的发展细胞遗传学市场。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场力量
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析
  • 专利情况

第 4 章分子细胞遗传学市场：副产品

  • 概览
    • 市场规模和预测
  • 设备
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 消耗品
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 软件和服务
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章分子细胞遗传学市场：按技术分类

  • 概览
    • 市场规模和预测
  • 比较基因组杂交
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：国家分析
    • 比较基因组杂交分子细胞遗传学市场：按类型分类
      • 基于芯片的比较基因组杂交市场规模和预测：按地区
      • 标准比较基因组杂交市场规模和预测：按地区
  • 萤光原位杂交
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章分子细胞遗传学市场：按应用

  • 概览
    • 市场规模和预测
  • 遗传性疾病
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 癌症
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 个性化医疗
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章分子细胞遗传学市场：按最终用户分类

  • 概览
    • 市场规模和预测
  • 临床和研究机构
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 製药公司、生物技术公司
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 8 章分子细胞遗传学市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机遇
    • 北美市场规模和预测：按产品
    • 北美市场规模和预测：按技术分类
      • 北美比较基因组杂交分子细胞遗传学市场：按类型
    • 北美市场规模和预测：按应用分类
    • 北美市场的市场规模和预测：按最终用户分类
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机遇
    • 欧洲市场规模和预测：按产品
    • 欧洲市场规模和预测：按技术分类
      • 欧洲比较基因组杂交分子细胞遗传学市场：按类型分类
    • 欧洲市场规模和预测：按应用分类
    • 欧洲市场规模和预测：按最终用户分类
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机遇
    • 亚太市场规模和预测：按产品
    • 亚太市场规模和预测：按技术分类
      • 亚太地区比较基因组杂交分子细胞遗传学市场：按类型分类
    • 亚太地区的市场规模和预测：按应用分类
    • 亚太市场规模和预测：按最终用户分类
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 澳大利亚
      • 印度
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机遇
    • LAMEA 市场规模和预测：按产品
    • LAMEA 市场规模和预测：按技术分类
      • LAMEA 比较基因组杂交分子细胞遗传学市场：按类型分类
    • LAMEA 市场规模和预测：按应用分类
    • LAMEA 市场规模和预测：按最终用户分类
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 拉美其他地区

第九章商业条件

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第十章公司简介

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Applied Spectral Imaging
  • Cyto Test Inc.
  • Danaher Corporation（Cephied）
  • Empire Genomics, LLC.
  • Genial Genetic Solutions Ltd.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Sema4 Holdings Corp.
  • Sysmex Corporation（Oxford Gene Technology）
  • Thermo Fisher Scientific Inc.
Product Code: A12298

The global molecular cytogenetics market was valued at $2,233.5 million in 2021, and is projected to reach $5,146.55 million by 2031, registering a CAGR of 8.7%.

Molecular cytogenetics includes the chromosome biology and the use of molecular cytogenetic methods in biology and medicine. These include the structural and functional establishment of the chromosome and nucleus, genome variation, expression, and evolution, chromosome abnormalities, and genomic variations in tumor genetics and medical genetics. The testing includes identifying a specific gene or gene locus (molecular) with direct visualization of the cells and chromosomes under a fluorescence microscope and is far from being outdated and is actively involved in up-to-date diagnostics and research.

According to National Center for Biotechnology Information (NCBI), an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. This prevalence of cancer diseases among all age groups owing to changes (mutations) to the DNA within cells, will lead to the increase in the demand for diagnostic techniques of molecular cytogenetics.

Furthermore, the growth of the molecular cytogenetics market is anticipated to be facilitated by the introduction of numerous cutting-edge diagnostic technologies by the biotechnology companies, an increase in demand for accurate diagnosis of serious cancer diseases, and the availability of interventional pathologist with the necessary training in developed economies.

In addition, advancements in molecular cytogenetics, increase in incidence of genetic disorders & cancer and rise in awareness & acceptance of personalized medicines, are some of the factors that are boosting the market growth. The development of the techniques including interphase fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), multicolor karyotyping, telomere FISH, primed in situ labelling (PRINS), and telomere FISH, have caused the expansion of the market. However, the market is expected to be significantly constrained in the near future by factors such as high cost associated with the procedure.

In addition, the use of molecular pathology in disease diagnosis, disease prevention, and treatment is now possible using the molecular cytogenetics. For instance, the development of the BioPrime Total Genomic Labeling System by the Thermo Fisher Scientific, which is a complete genomic DNA labeling system designed for use in array comparative genomic hybridization applications (aCGH) that allows for better call rates with precious samples.

The molecular cytogenetics market is segmented on the basis of product, technique, application, end user and region. By product, it is divided into instruments, consumables, and software & services. On the basis of technique, the market is segmented into comparative genomic hybridization, fluorescence in situ hybridization and others. Further, the comparative genomic hybridization segment is divided into array-based comparative genomic hybridization and standard comparative genomic hybridization. By application, the market is segmented into genetic disorders, cancer, personalized medicine and others. According to the end user, the market is segmented into clinical & research laboratories, pharmaceutical & biotechnology companies and others (academic research institutes, contract research organization [CRO]). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging, Cyto Test Inc., Danaher Corporation (Cephied), Empire Genomics, LLC., Genial Genetic Solutions Ltd., Illumina, Inc., Perkinelmer, Inc., Sema4 Holdings Corp., Sysmex Corporation (Oxford Gene Technology) and Thermo Fisher Scientific Inc. and among others.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the molecular cytogenetics market analysis from 2021 to 2031 to identify the prevailing molecular cytogenetics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the molecular cytogenetics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global molecular cytogenetics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Instruments
  • Consumables
  • Software and Services

By Technique

  • Comparative Genomic Hybridization
    • Type
    • Array-Based Comparative Genomic Hybridization
    • Standard Comparative Genomic Hybridization
  • Fluorescence in Situ Hybridization
  • Others

By Application

  • Genetic Disorders 
  • Cancer 
  • Personalized Medicines
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Others
  • Clinical and Research Laboratories

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Applied Spectral Imaging
    • Cyto Test Inc.
    • Danaher Corporation (Cephied)
    • Empire Genomics, LLC.
    • Genial Genetic Solutions Ltd.
    • Illumina, Inc.
    • PerkinElmer, Inc.
    • Sema4 Holdings Corp.
    • Sysmex Corporation (Oxford Gene Technology)
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Instruments
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Consumables
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Software and Services
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Comparative Genomic Hybridization
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
      • 5.2.4.1 Array-Based Comparative Genomic Hybridization Market size and forecast, by region
      • 5.2.4.2 Standard Comparative Genomic Hybridization Market size and forecast, by region
  • 5.3 Fluorescence in Situ Hybridization
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Genetic Disorders 
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Cancer 
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Personalized Medicines
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Others
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country

CHAPTER 7: MOLECULAR CYTOGENETICS MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Clinical and Research Laboratories
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Pharmaceutical and Biotechnology Companies
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country
  • 7.4 Others
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market analysis by country

CHAPTER 8: MOLECULAR CYTOGENETICS MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Product
    • 8.2.3 North America Market size and forecast, by Technique
      • 8.2.3.1 North America Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
    • 8.2.4 North America Market size and forecast, by Application
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Product
      • 8.2.6.1.2 Market size and forecast, by Technique
      • 8.2.6.1.3 Market size and forecast, by Application
      • 8.2.6.1.4 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Product
      • 8.2.6.2.2 Market size and forecast, by Technique
      • 8.2.6.2.3 Market size and forecast, by Application
      • 8.2.6.2.4 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Product
      • 8.2.6.3.2 Market size and forecast, by Technique
      • 8.2.6.3.3 Market size and forecast, by Application
      • 8.2.6.3.4 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Product
    • 8.3.3 Europe Market size and forecast, by Technique
      • 8.3.3.1 Europe Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
    • 8.3.4 Europe Market size and forecast, by Application
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Product
      • 8.3.6.1.2 Market size and forecast, by Technique
      • 8.3.6.1.3 Market size and forecast, by Application
      • 8.3.6.1.4 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by Product
      • 8.3.6.2.2 Market size and forecast, by Technique
      • 8.3.6.2.3 Market size and forecast, by Application
      • 8.3.6.2.4 Market size and forecast, by End User
      • 8.3.6.3 UK
      • 8.3.6.3.1 Market size and forecast, by Product
      • 8.3.6.3.2 Market size and forecast, by Technique
      • 8.3.6.3.3 Market size and forecast, by Application
      • 8.3.6.3.4 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by Product
      • 8.3.6.4.2 Market size and forecast, by Technique
      • 8.3.6.4.3 Market size and forecast, by Application
      • 8.3.6.4.4 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by Product
      • 8.3.6.5.2 Market size and forecast, by Technique
      • 8.3.6.5.3 Market size and forecast, by Application
      • 8.3.6.5.4 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Product
      • 8.3.6.6.2 Market size and forecast, by Technique
      • 8.3.6.6.3 Market size and forecast, by Application
      • 8.3.6.6.4 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Product
    • 8.4.3 Asia-Pacific Market size and forecast, by Technique
      • 8.4.3.1 Asia-Pacific Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
    • 8.4.4 Asia-Pacific Market size and forecast, by Application
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Market size and forecast, by Product
      • 8.4.6.1.2 Market size and forecast, by Technique
      • 8.4.6.1.3 Market size and forecast, by Application
      • 8.4.6.1.4 Market size and forecast, by End User
      • 8.4.6.2 China
      • 8.4.6.2.1 Market size and forecast, by Product
      • 8.4.6.2.2 Market size and forecast, by Technique
      • 8.4.6.2.3 Market size and forecast, by Application
      • 8.4.6.2.4 Market size and forecast, by End User
      • 8.4.6.3 Australia
      • 8.4.6.3.1 Market size and forecast, by Product
      • 8.4.6.3.2 Market size and forecast, by Technique
      • 8.4.6.3.3 Market size and forecast, by Application
      • 8.4.6.3.4 Market size and forecast, by End User
      • 8.4.6.4 India
      • 8.4.6.4.1 Market size and forecast, by Product
      • 8.4.6.4.2 Market size and forecast, by Technique
      • 8.4.6.4.3 Market size and forecast, by Application
      • 8.4.6.4.4 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by Product
      • 8.4.6.5.2 Market size and forecast, by Technique
      • 8.4.6.5.3 Market size and forecast, by Application
      • 8.4.6.5.4 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Market size and forecast, by Product
      • 8.4.6.6.2 Market size and forecast, by Technique
      • 8.4.6.6.3 Market size and forecast, by Application
      • 8.4.6.6.4 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Product
    • 8.5.3 LAMEA Market size and forecast, by Technique
      • 8.5.3.1 LAMEA Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
    • 8.5.4 LAMEA Market size and forecast, by Application
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Product
      • 8.5.6.1.2 Market size and forecast, by Technique
      • 8.5.6.1.3 Market size and forecast, by Application
      • 8.5.6.1.4 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Product
      • 8.5.6.2.2 Market size and forecast, by Technique
      • 8.5.6.2.3 Market size and forecast, by Application
      • 8.5.6.2.4 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by Product
      • 8.5.6.3.2 Market size and forecast, by Technique
      • 8.5.6.3.3 Market size and forecast, by Application
      • 8.5.6.3.4 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by Product
      • 8.5.6.4.2 Market size and forecast, by Technique
      • 8.5.6.4.3 Market size and forecast, by Application
      • 8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 Abbott Laboratories
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Agilent Technologies Inc.
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Applied Spectral Imaging
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Cyto Test Inc.
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Danaher Corporation (Cephied)
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Empire Genomics, LLC.
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Genial Genetic Solutions Ltd.
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Illumina, Inc.
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 PerkinElmer, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 Sema4 Holdings Corp.
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments
  • 10.11 Sysmex Corporation (Oxford Gene Technology)
    • 10.11.1 Company overview
    • 10.11.2 Company snapshot
    • 10.11.3 Operating business segments
    • 10.11.4 Product portfolio
    • 10.11.5 Business performance
    • 10.11.6 Key strategic moves and developments
  • 10.12 Thermo Fisher Scientific Inc.
    • 10.12.1 Company overview
    • 10.12.2 Company snapshot
    • 10.12.3 Operating business segments
    • 10.12.4 Product portfolio
    • 10.12.5 Business performance
    • 10.12.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 2. MOLECULAR CYTOGENETICS MARKET, FOR INSTRUMENTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. MOLECULAR CYTOGENETICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. MOLECULAR CYTOGENETICS MARKET, FOR CONSUMABLES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. MOLECULAR CYTOGENETICS MARKET FOR CONSUMABLES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. MOLECULAR CYTOGENETICS MARKET, FOR SOFTWARE AND SERVICES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. MOLECULAR CYTOGENETICS MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 9. MOLECULAR CYTOGENETICS MARKET, FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 12. MOLECULAR CYTOGENETICS MARKET, FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. MOLECULAR CYTOGENETICS MARKET, FOR STANDARD COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. MOLECULAR CYTOGENETICS MARKET, FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. MOLECULAR CYTOGENETICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. MOLECULAR CYTOGENETICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 19. MOLECULAR CYTOGENETICS MARKET, FOR GENETIC DISORDERS , BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS , BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. MOLECULAR CYTOGENETICS MARKET, FOR CANCER , BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. MOLECULAR CYTOGENETICS MARKET FOR CANCER , BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. MOLECULAR CYTOGENETICS MARKET, FOR PERSONALIZED MEDICINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 25. MOLECULAR CYTOGENETICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. MOLECULAR CYTOGENETICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 27. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 28. MOLECULAR CYTOGENETICS MARKET, FOR CLINICAL AND RESEARCH LABORATORIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. MOLECULAR CYTOGENETICS MARKET FOR CLINICAL AND RESEARCH LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. MOLECULAR CYTOGENETICS MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 31. MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. MOLECULAR CYTOGENETICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 33. MOLECULAR CYTOGENETICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 34. MOLECULAR CYTOGENETICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 35. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 36. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 37. NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 39. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 40. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 41. U.S. MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 42. U.S. MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 43. U.S. MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 44. U.S. MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 45. CANADA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 46. CANADA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 47. CANADA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 48. CANADA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 49. MEXICO MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 50. MEXICO MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 51. MEXICO MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 52. MEXICO MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 53. EUROPE MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 54. EUROPE MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 55. EUROPE COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 56. EUROPE MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 57. EUROPE MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 58. EUROPE MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 59. GERMANY MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 60. GERMANY MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 61. GERMANY MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 62. GERMANY MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 63. FRANCE MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 64. FRANCE MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 65. FRANCE MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 66. FRANCE MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 67. UK MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 68. UK MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 69. UK MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 70. UK MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 71. ITALY MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 72. ITALY MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 73. ITALY MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 74. ITALY MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 75. SPAIN MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 76. SPAIN MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 77. SPAIN MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 78. SPAIN MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 79. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 80. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 81. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 82. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 84. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 85. ASIA-PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 87. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 88. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 89. JAPAN MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 90. JAPAN MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 91. JAPAN MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 92. JAPAN MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 93. CHINA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 94. CHINA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 95. CHINA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 96. CHINA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 97. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 98. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 99. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 100. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 101. INDIA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 102. INDIA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 103. INDIA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 104. INDIA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 105. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 106. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 107. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 108. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 109. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 110. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 111. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 112. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 113. LAMEA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 114. LAMEA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 115. LAMEA COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 116. LAMEA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 117. LAMEA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 118. LAMEA MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 119. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 120. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 121. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 122. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 123. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 124. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 125. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 126. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 127. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 128. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 129. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 130. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 131. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 132. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 133. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 134. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 135.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 136.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 137.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 138.ABBOTT LABORATORIES: NET SALES,
  • TABLE 139.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 140.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 141.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 142.AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 143.AGILENT TECHNOLOGIES INC.: NET SALES,
  • TABLE 144.AGILENT TECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 145.APPLIED SPECTRAL IMAGING: COMPANY SNAPSHOT
  • TABLE 146.APPLIED SPECTRAL IMAGING: OPERATING SEGMENTS
  • TABLE 147.APPLIED SPECTRAL IMAGING: PRODUCT PORTFOLIO
  • TABLE 148.APPLIED SPECTRAL IMAGING: NET SALES,
  • TABLE 149.APPLIED SPECTRAL IMAGING: KEY STRATERGIES
  • TABLE 150.CYTO TEST INC.: COMPANY SNAPSHOT
  • TABLE 151.CYTO TEST INC.: OPERATING SEGMENTS
  • TABLE 152.CYTO TEST INC.: PRODUCT PORTFOLIO
  • TABLE 153.CYTO TEST INC.: NET SALES,
  • TABLE 154.CYTO TEST INC.: KEY STRATERGIES
  • TABLE 155.DANAHER CORPORATION (CEPHIED): COMPANY SNAPSHOT
  • TABLE 156.DANAHER CORPORATION (CEPHIED): OPERATING SEGMENTS
  • TABLE 157.DANAHER CORPORATION (CEPHIED): PRODUCT PORTFOLIO
  • TABLE 158.DANAHER CORPORATION (CEPHIED): NET SALES,
  • TABLE 159.DANAHER CORPORATION (CEPHIED): KEY STRATERGIES
  • TABLE 160.EMPIRE GENOMICS, LLC.: COMPANY SNAPSHOT
  • TABLE 161.EMPIRE GENOMICS, LLC.: OPERATING SEGMENTS
  • TABLE 162.EMPIRE GENOMICS, LLC.: PRODUCT PORTFOLIO
  • TABLE 163.EMPIRE GENOMICS, LLC.: NET SALES,
  • TABLE 164.EMPIRE GENOMICS, LLC.: KEY STRATERGIES
  • TABLE 165.GENIAL GENETIC SOLUTIONS LTD.: COMPANY SNAPSHOT
  • TABLE 166.GENIAL GENETIC SOLUTIONS LTD.: OPERATING SEGMENTS
  • TABLE 167.GENIAL GENETIC SOLUTIONS LTD.: PRODUCT PORTFOLIO
  • TABLE 168.GENIAL GENETIC SOLUTIONS LTD.: NET SALES,
  • TABLE 169.GENIAL GENETIC SOLUTIONS LTD.: KEY STRATERGIES
  • TABLE 170.ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 171.ILLUMINA, INC.: OPERATING SEGMENTS
  • TABLE 172.ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 173.ILLUMINA, INC.: NET SALES,
  • TABLE 174.ILLUMINA, INC.: KEY STRATERGIES
  • TABLE 175.PERKINELMER, INC.: COMPANY SNAPSHOT
  • TABLE 176.PERKINELMER, INC.: OPERATING SEGMENTS
  • TABLE 177.PERKINELMER, INC.: PRODUCT PORTFOLIO
  • TABLE 178.PERKINELMER, INC.: NET SALES,
  • TABLE 179.PERKINELMER, INC.: KEY STRATERGIES
  • TABLE 180.SEMA4 HOLDINGS CORP.: COMPANY SNAPSHOT
  • TABLE 181.SEMA4 HOLDINGS CORP.: OPERATING SEGMENTS
  • TABLE 182.SEMA4 HOLDINGS CORP.: PRODUCT PORTFOLIO
  • TABLE 183.SEMA4 HOLDINGS CORP.: NET SALES,
  • TABLE 184.SEMA4 HOLDINGS CORP.: KEY STRATERGIES
  • TABLE 185.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): COMPANY SNAPSHOT
  • TABLE 186.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): OPERATING SEGMENTS
  • TABLE 187.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): PRODUCT PORTFOLIO
  • TABLE 188.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): NET SALES,
  • TABLE 189.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): KEY STRATERGIES
  • TABLE 190.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 191.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 192.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 193.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 194.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.MOLECULAR CYTOGENETICS MARKET SEGMENTATION
  • FIGURE 2.MOLECULAR CYTOGENETICS MARKET,2021-2031
  • FIGURE 3.MOLECULAR CYTOGENETICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.MOLECULAR CYTOGENETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.MOLECULAR CYTOGENETICS MARKET,BY PRODUCT,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CONSUMABLES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SOFTWARE AND SERVICES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 18.MOLECULAR CYTOGENETICS MARKET,BY TECHNIQUE,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF FLUORESCENCE IN SITU HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 22.MOLECULAR CYTOGENETICS MARKET,BY APPLICATION,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GENETIC DISORDERS  MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CANCER  MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 27.MOLECULAR CYTOGENETICS MARKET,BY END USER,2021(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF CLINICAL AND RESEARCH LABORATORIES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
  • FIGURE 31.MOLECULAR CYTOGENETICS MARKET BY REGION,2021
  • FIGURE 32.U.S. MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 33.CANADA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 34.MEXICO MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 35.GERMANY MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 36.FRANCE MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 37.UK MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 38.ITALY MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 39.SPAIN MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF EUROPE MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 41.JAPAN MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 42.CHINA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 43.AUSTRALIA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 44.INDIA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 45.SOUTH KOREA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 47.BRAZIL MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 48.SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 49.SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 50.REST OF LAMEA MOLECULAR CYTOGENETICS MARKET,2021-2031($MILLION)
  • FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 55.COMPETITIVE DASHBOARD
  • FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 57.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 58.AGILENT TECHNOLOGIES INC..: NET SALES ,($MILLION)
  • FIGURE 59.APPLIED SPECTRAL IMAGING.: NET SALES ,($MILLION)
  • FIGURE 60.CYTO TEST INC..: NET SALES ,($MILLION)
  • FIGURE 61.DANAHER CORPORATION (CEPHIED).: NET SALES ,($MILLION)
  • FIGURE 62.EMPIRE GENOMICS, LLC..: NET SALES ,($MILLION)
  • FIGURE 63.GENIAL GENETIC SOLUTIONS LTD..: NET SALES ,($MILLION)
  • FIGURE 64.ILLUMINA, INC..: NET SALES ,($MILLION)
  • FIGURE 65.PERKINELMER, INC..: NET SALES ,($MILLION)
  • FIGURE 66.SEMA4 HOLDINGS CORP..: NET SALES ,($MILLION)
  • FIGURE 67.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY).: NET SALES ,($MILLION)
  • FIGURE 68.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)